Background
Rheumatoid arthritis (RA) is a chronic, systemic and progressive inflammatory disorder primarily characterized by persistent chronic synovitis, progressive erosions, and cartilage destruction, which may cause deformed and painful joints, even resulting in loss of function [1] . RA affects 0.5-1% adults in the developed world, with 5-50 per 100,000 people being newly diagnosed with the condition, annually. Furthermore, the onset of RA is most frequent in females and the elderly [2] . RA, without intervention, may eventually cause joint damage, disability, reduced quality of life, cardiovascular events and other comorbidities [3, 4] . Although a variety of environmental and behavioral factors confer a high risk of developing RA, genetic factors are suspected to account for up to 50% of the risk for developing RA [5] .
Vascular endothelial growth factor (VEGF) is an important signaling protein and a secreted ligand released by cells to stimulate vasculogenesis and angiogenesis. VEGF plays an important role in regulating angiogenesis through promoting vascular endothelial cell growth, migration, and lumen formation [6] . In addition, VEGF is also capable of inducing proinflammatory change, seen in chronic inflammation, which involves leukocyte accumulation, collagen deposition, and blood vessel remodeling [7] . VEGF is also released by inflammatory cells and, in turn may represent the inflammatory component in many disease processes [8] . In this context, enhanced serum VEGF levels are associated with the duration and severity in many disorders, such as RA [9] . The human VEGF gene is localized on chromosome 6p12, and contains of 8 exons. The VEGF gene is also an independent risk factor for RA severity, and correlates with multiple disease parameters, such as disease activity, joint damage, and functional disability [10] . Two common single-nucleotide polymorphisms (SNPs), rs833070 (G>A) located in intron 2 and rs3025030 (G>C) located in intron 5, are suspected to result in altered protein expression of VEGF and have strong links to the onset of RA, although some studies dispute such a link [11] . Our present study evaluates the common SNPs in the VEGFA gene [rs833070 (G>A) and rs3025030 (G>C)] for their influences on the circulating levels of VEGF protein and their effects on disease activity and synovial lesions in RA.
Material and Methods

Ethics statement
The study was approved by the Ethics Committee of the Zhujiang Hospital, Southern Medical University. The written informed consent was provided by each eligible patient and the study conformed to the Declaration of Helsinki [12] .
Patients
This study was conducted between October 2010 and May 2012 on a population of RA patients (n=98) from Zhujiang Hospital, Southern Medical University. Patients with RA who satisfied all aspects of the 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for RA were recruited to the study [13] . There were 32 male and 66 female RA patients, with an age range of 18-80 years (mean age, 50.82±12.53 years) and mean disease duration of 3.0 years (range, 0.8-8.0 years). A group of 100 healthy volunteers (male, 35; female, 65; age range, 15-85 years; mean age, 48.67±13.41 years) were enrolled as the control group from the Medical Examination Center of the Shengjing Hospital of China Medical University. No statistical difference in age or sex existed between the RA group and the control group. Patients with systemic lupus erythematosus (SLE), Sjögren syndrome (SS), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), polymyositis (PM), dermatomyositis (DM), other autoimmune diseases, hereditary diseases, severe heart, lung, liver, or kidney dysfunction, benign or malignant tumors, or other related diseases were excluded from this study.
Clinical data collection
General clinical data of all the study subjects such as age, sex, disease duration, present and past medical history, and the history of hereditary disease were collected and recorded. Common clinical laboratory parameters for RA including routine blood test, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and acute C-reactive protein (CRP) were collected.
Detection of VEGF polymorphisms
Morning fasting venous blood samples (2 ml) were collected from all subjects. EDTA was used as an anticoagulant for blood collection. Genomic DNA was extracted from the white blood cells (WBCs) collected from venous blood by using a DNA Extraction Kit (Tiangen Biotech, Beijing, China) according to the manufacturer's protocol. The SNP genotyping was conducted using the matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) (Sequenom Inc., San Diego, CA, USA) [14] . The primers ( to inactivate SAP, and stored at 4°C. Next, the iPlex reaction system was prepared and added into the 384-well plate, and the single-base extension reaction was conducted under the following conditions: at 94°C for 30 s, at 94°C for 5 s, at 52°C for 5 s, at 80°C for 5 s, at 72°C for 3 min, and storing at 4°C. The purification of PCR products was performed by demineralization with resin. The DNA samples were transferred from the 384-well plate onto the MassARRAY SpectroCHIP covered with matrix, and detected with the mass spectrometer. The genotyping analysis was performed by using the MassARRAY ® TYPER software.
Enzyme-linked immunosorbent assay (ELISA)
The serum concentrations of VEGF were measured by the ELISA method using an ELISA kit provided by Wuhan Boshide Company (Wuhan, China) in accordance with the manufacturer's instructions [15] .
Disease activity score (DAS)
A total of 28 joints, including shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints of hands, and knee joints, were scored by DAS scoring system [16] . The number of swollen and tender joints in each RA patient was examined and recorded, and the DAS28 score was calculated by combining the ESR and self-evaluation in patients with RA.
[n1, the number of tender joints; n2, the number of swollen joints; n3, ESR (mm/h); n4, health evaluation in RA patients]. The DAS28 score of <2.6 is considered as remission, 2.6-3.2 as low mobility, 3.3-5.1 as moderate mobility, and >5.1 as frequent mobility.
Ultrasonography
The ultrasonic examination was performed using a Siemens ACUSON S2000™ color Doppler (Siemens, Erlangen, Germany), with the probe frequency of 8-13 MHZ. The 28 joints of each RA patient were examined using direct contact method. All patients adopted the supine or sitting position, adjusted based on the examined joints, with the examined joint fully exposed.
An experienced physician with ultrasound expertise, who did not know the disease status and treatment status of the patients, monitored the ultrasound examinations.
Ultrasonic examination
Based on the classification standard of Walther, the synovial thickness was classified into 4 grades: grade I, no synovial hyperplasia and thickness <2 mm; grade II, mild synovial hyperplasia and thickness=2-4 mm; grade III, moderate synovial hyperplasia and thickness=5-9 mm; grade IV, severe synovial hyperplasia and thickness >9 mm [17] . Joint effusion in joint scotoma (anteroposterior diameter) was determined based on different joint size and position: knee suprapatellar bursa scotoma >4 cm is considered as joint effusion; medial and lateral knee scotoma >2 cm as joint effusion; scotoma of shoulder joins, elbow joints, and wrist joints, metacarpophalangeal and proximal interphalangeal joints >2 cm as joint effusion.
Power Doppler evaluation
The semi-quantitative signal of each point of synovium in the 28 joints was observed and classified: grade 0, no signal or blood flow; grade 1, slight signal, and single or independent vascular signals less than 3; grade 2, moderate fusion vessel, and more than 3 independent signals, or fusion signals less than half the synovial region; grade 3, significant signal, and visible vascular signals in more than half the medial region of the joints.
Recording items
Recording items consisted of the followings: (1) US joint count SH: the number of joints with thickened synovium; (2) US joint count SF: the number of joints with effusion; (3) US joint count PD: the number of joints with energy signals; (4) US index SH: total synovial thickening score, which was the sum of the synovial thickening score of the 28 joints; (5) US index SF: total joint effusion score, which was the sum of joint effusion score of the 28 joints; (6) total sharp scores (TSS): the sum of the highest power Doppler score of each joint. 
Statistical analysis
Statistical analysis was conducted using SPSS 18 software (SPSS Inc., Chicago, IL, USA), and the data are represented as means ± standard deviation (SD), median, or percentage. The statistical comparison between 2 groups was conducted using the t-test or the analysis of variance (ANOVA). Genotype distribution in the control group was tested by Hardy-Weinberg equilibrium (HWE). The differences in genotype and allele distribution between the RA group and the control group are represented as odds ratio (OR) and 95% confidence interval (CI). P values for all tests are 2-tailed, and <0.05 was considered as statistically significant.
Results
Characteristics of RA patients Table 2 shows the demographic and clinical characteristics of 198 subjects, consisting of 98 RA patients and 100 controls, from a hospital based population at the time of recruitment. Comparisons between the RA group and the control group demonstrated that ESR, RF, acute CRP, and serum VEGF levels were significantly higher in patients with RA than in controls (all P<0.05). No statistical differences were seen in age, gender, WBC, red blood cell (RBC), hemoglobin (HGB) and platelet (PLT) count (all P>0.05).
Distributions of VEGF SNPs
The genotype and allele frequencies of the VEGF genetic polymorphisms, rs833070 (G>A) and rs3025030 (G>C), in RA patients and controls are displayed in (Figure 2 ).
Association of VEGF SNPs with disease severity in RA Association of VEGF SNPs with synovial lesions in RA
As illustrated in Table 6 , there was statistical significance in the positive rate of synovial thickening, joint effusion and synovial angiogenesis between different genotypes of VEGF rs833070 and rs3025030 (P<0.05). The positive rate of synovial thickening, joint effusion and synovial angiogenesis in RA patients carrying rs833070 AG and AA genotype was evidently higher than patients carrying rs833070 GG genotype (P<0.05). Similarly, the positive rate of synovial thickening, joint effusion and synovial angiogenesis in RA patients with rs3025030 GC and GG genotype was higher compared to RA patients with rs3025030 CC genotype (P<0.05).
Discussion
In the current study, we investigated the significance of 2 SNPs in VEGF gene, rs833070 and rs3025030, which alter VEGF protein levels in the serum. The association of these VEGF gene variations with circulating serum levels of VEGF, disease activity, and synovial lesions was systematically measured in RA patients. Additionally, we carried out genotyping in a hospitalbased case-control study in a cohort of 98 RA patients and 100 controls to obtain a comprehensive view of the disease parameters in relation to the genotypes under study.
The results of the SNP genotyping and ELISA based measurement of serum VEGF revealed that VEGF rs833070 AA genotype is related to higher serum VEGF level, and the same genotype and haplotype also occurred more frequently in RA patients. The GG genotype of VEGF rs3025030 was associated with a lower VEGF serum level, and the same genotype and haplotype showed a lower frequency in patients with RA, suggesting that VEGF rs833070 genetic polymorphisms is a significant risk factor in RA, while rs3025030 mutation in the VEGF gene might play a protective role in RA through lowering VEGF levels in serum. Previous studies have also reported enhanced serum VEGF levels in RA patients; however, the links to VEGF genetic variations as a mechanism to regulate serum VEGF levels, and leading to an increased or decreased risk of RA, are still unclear [10, 18] . It is hypothesized that VEGF polymorphisms influence VEGF gene transcription, resulting in altered serum levels of VEGF [5] . Although only a small change is observed in the absolute values of serum VEGF levels due to VEGF genetic polymorphisms, the disease outcomes show large differences and probably reflect a sustained activation of mechanisms promoting RA [19] . RA mainly results from pannus formation caused by synovial angiogenesis [20] . Furthermore, VEGF protein, one of the most potent inducers of angiogenesis, plays a vital role in activating angiogenesis in RA through up-regulation of the VEGF pathway [6] . Therefore, it is plausible to conclude that VEGF rs833070 polymorphism increases serum VEGF levels, and the higher VEGF serum levels confer increased risk of RA. On the other hand, VEGF rs3025030 polymorphism reduces VEGF protein levels in serum and decreases the onset of RA. Consistent with our observation, Ozgonenel et al. also demonstrated that higher VEGF levels are correlated to late phase and high risk of RA, independent of age and sex [10] . Moreover, Chen et al., who studied a sample of 413 hospitalbased RA patients of Caucasian origin, reported that the T allele at VEGF rs3025039 could influence the onset of RA [21] . Additionally, a previous meta-analysis, which studied a total of 24 independent studies associated with autoimmune disease, revealed that VEGF polymorphisms were related to the susceptibility to RA [22] . In addition, the findings from our study show that rs833070 AA genotype in the VEGF gene was closely associated with high disease activity in RA, and both rs833070 and rs3025030 variants in the VEGF gene were positively associated with synovial thickening, joint effusion, and synovial angiogenesis, indicating that VEGF genetic polymorphisms might play roles in promoting disease activity, synovial thickening, joint effusion, and synovial angiogenesis in RA. Serum VEGF levels were positively correlated to ESR, RF, and CRP, which are independent variables for disease activity [23] . In addition, higher VEGF in serum might increase vascular permeability, which in turn contributes to joint effusion and joint swelling, which is related to the synovial thickening seen in RA [24] . As serum VEGF level rises, the number of swollen and sensitive joints, which is one of the DAS28 calculation parameters, rises as expected, contributing to high DASs [25] . The synovial angiogenesis in RA might be explained by the role of VEGF in angiogenesis [26] .
A previous study showed that VEGF plays a central role in RArelated joint destruction, as evidenced by the observed radiologic changes and increased DAS in patients with high serum VEGF levels [27] . As well, Ozgonenel et al. reported that higher VEGF levels are associated with late phase and high disease activity in RA, independent of age and sex [9] . Chen et al. also have documented that genetic variation in the VEGF gene is associated with serum VEGF levels in RA, and shows an association with disease activity in RA patients who have never smoked, independent of serum VEGF levels [10] . One limitations of our study is that this was a hospital-based case-control study, hence the subjects were not representative of general population; nevertheless, this case-control study still had the ability to contribute to relatively reliable results. Another limitation is that the polymorphisms were evaluated based on their function, and may not supply a comprehensive view of the genetic variability of VEGF; therefore, further fine-mapping studies are needed. In addition, the sample size of this study was too small to investigate the low penetrance effect of the SNPs.
Conclusions
Our study shows that variants in the VEGF gene might serve as biomarkers for disease activity and synovial lesions in RA, and are a useful biochemical parameter to assess the treatment effectiveness in RA.
